Opportunity Information: Apply for PAR 10 016
Apply for PAR 10 016
- The National Institutes of Health in the education environment health sector is offering a public funding opportunity titled "Enabling Technologies in DNA Repair Research (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.393 Cancer Cause and Prevention Research.
- This funding opportunity was created on Oct 29, 2009 and posted on Oct 29, 2009.
- Applicants must submit their applications by Jan 10, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity "Enabling Technologies in DNA Repair Research (R21)" (PAR-10-016) supports short, exploratory projects aimed at building practical tools that make it easier to move DNA damage and DNA repair research from basic lab settings into real-world human studies. The central idea is to fund multidisciplinary teams that can create or significantly improve technologies and assays that measure how well DNA repair works in people, either as an overall (global) DNA repair capacity measure or as pathway-specific readouts that capture responses in individual DNA repair pathways after exposure to DNA damaging agents. The intended end users are clinical and population researchers who need reliable, scalable ways to quantify DNA damage responses in exposed individuals, including in epidemiological studies and clinical research contexts.
A major emphasis of this FOA is on developing assays that are not only scientifically sound but also reproducible and practical for studies involving many participants. To get there, the announcement highlights the importance of identifying and verifying biomarkers that consistently reflect specific DNA repair activities or mutagenic outcomes. In other words, applicants are encouraged to focus on measurable biological signals that can serve as dependable indicators of repair pathway activation, repair efficiency, or downstream consequences like mutation formation, with the explicit goal of turning those indicators into usable assays. The FOA also encourages field testing or pilot testing, which signals that projects can include early real-world validation steps rather than stopping at proof-of-concept work in a highly controlled lab environment.
From a project design standpoint, the NIH is looking for enabling technologies: methods, tools, and measurement platforms that lower the barriers to studying DNA damage response in humans at scale. That can include brand-new assay approaches for detecting DNA damage and repair, as well as meaningful upgrades to existing techniques that improve sensitivity, specificity, throughput, cost, standardization, or ease of deployment. A recurring requirement is that the resulting technologies should be appropriate for epidemiological and clinical studies, which typically means they should work with accessible human samples, produce consistent results across operators and sites, and be scalable to larger cohorts without becoming prohibitively expensive or labor-intensive.
This opportunity uses the NIH Exploratory/Developmental R21 grant mechanism, which is generally meant for early-stage, high-impact technology development or innovative concepts that need initial support to establish feasibility and generate compelling preliminary data. The maximum project period is two years. The direct cost cap is 275,000 total over the two-year period, with an additional constraint that no more than 200,000 in direct costs can be requested in any single year. As with many NIH opportunities, the number of awards is not fixed and depends on available funds and the quality and volume of applications received.
In terms of who can apply, eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), for-profit organizations other than small businesses, small businesses, state governments, and certain Native American tribal governments and tribal organizations. The eligibility list also explicitly includes a range of mission-focused and community-anchored entities such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, tribally controlled colleges and universities (TCCUs), faith-based or community-based organizations, regional organizations, US territories or possessions, and non-US (foreign) organizations. The announcement indicates there is no cost sharing or matching requirement.
Administratively, the agency is the National Institutes of Health. The opportunity was posted on October 29, 2009, with an original and current closing date of January 10, 2010, and an archive date of February 10, 2010, meaning it is an archived historical FOA rather than an open competition today. The related CFDA program areas listed include Environmental Health (93.113) and Cancer Cause and Prevention Research (93.393), reflecting the strong relevance of DNA damage and repair measurement technologies to environmental exposure science and cancer prevention research. The full announcement was hosted through the NIH grants guide page associated with PAR-10-016.
Frequently Asked Questions (FAQs)
What is the funding opportunity "Enabling Technologies in DNA Repair Research (R21)" (PAR-10-016)?
It is an NIH funding opportunity that supports short, exploratory projects focused on building practical tools that help move DNA damage and DNA repair research from basic laboratory settings into real-world human studies. The focus is on enabling technologies and assays that can measure how well DNA repair works in people.
What is the main goal of this FOA?
The main goal is to fund multidisciplinary teams that can create or significantly improve technologies and assays to quantify DNA damage responses and DNA repair capacity in humans, in ways that are usable for clinical research and population-based (epidemiological) studies.
What types of measurements is NIH looking for under this FOA?
The FOA emphasizes assays that can measure DNA repair in humans either as (1) global DNA repair capacity or (2) pathway-specific readouts that capture responses in individual DNA repair pathways after exposure to DNA damaging agents.
Who are the intended end users of the technologies developed in this program?
The intended end users are clinical and population researchers who need reliable, scalable ways to quantify DNA damage responses in exposed individuals, including in epidemiological studies and clinical research settings.
What does "enabling technologies" mean in the context of this FOA?
In this FOA, enabling technologies are methods, tools, and measurement platforms that lower practical barriers to studying DNA damage response in humans at scale. This includes entirely new assay approaches as well as meaningful upgrades to existing techniques.
What kinds of improvements to existing techniques are encouraged?
The FOA explicitly encourages improvements that make assays more suitable for large human studies, such as better sensitivity, specificity, throughput, cost efficiency, standardization, reproducibility, and ease of deployment.
Does the FOA emphasize reproducibility and practicality for large studies?
Yes. A major emphasis is on developing assays that are scientifically sound while also reproducible and practical for studies involving many participants.
What role do biomarkers play in this funding opportunity?
Biomarker identification and verification are highlighted as important steps toward assays that consistently reflect specific DNA repair activities or mutagenic outcomes. Applicants are encouraged to focus on measurable biological signals that can serve as dependable indicators of repair pathway activation, repair efficiency, or downstream consequences such as mutation formation, and then translate those indicators into usable assays.
Are projects expected to include validation beyond proof-of-concept lab work?
The FOA encourages field testing or pilot testing, indicating that projects may include early real-world validation steps and do not need to stop at proof-of-concept work only under highly controlled laboratory conditions.
What settings should the resulting assays be appropriate for?
The resulting technologies should be appropriate for epidemiological and clinical studies. This generally implies compatibility with accessible human samples, consistent results across operators and sites, and scalability to larger cohorts without becoming prohibitively expensive or labor-intensive.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH Exploratory/Developmental R21 grant mechanism, which is intended for early-stage, potentially high-impact technology development or innovative concepts that need initial support to establish feasibility and generate preliminary data.
What is the maximum project period?
The maximum project period is two years.
What is the direct cost budget limit for this R21?
The direct cost cap is $275,000 total over the two-year period, with the additional constraint that no more than $200,000 in direct costs can be requested in any single year.
Is cost sharing or matching required?
No. The announcement indicates there is no cost sharing or matching requirement.
How many awards will NIH make under this FOA?
The number of awards is not fixed. Awards depend on available funds and the quality and volume of applications received.
Which agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
Who is eligible to apply?
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), for-profit organizations other than small businesses, small businesses, state governments, and certain Native American tribal governments and tribal organizations.
Are any specific institution types explicitly included?
Yes. The eligibility list explicitly includes historically Black colleges and universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, tribally controlled colleges and universities (TCCUs), faith-based or community-based organizations, regional organizations, US territories or possessions, and non-US (foreign) organizations.
Does this FOA allow applications from non-US (foreign) organizations?
Yes. Non-US (foreign) organizations are explicitly included in the eligibility list.
What are the relevant CFDA program areas for this FOA?
The related CFDA program areas listed include Environmental Health (93.113) and Cancer Cause and Prevention Research (93.393), reflecting the relevance of DNA damage and repair measurement technologies to exposure science and cancer prevention research.
When was this FOA posted, and what were the closing dates?
The opportunity was posted on October 29, 2009. The original and current closing date was January 10, 2010. The archive date was February 10, 2010.
Is PAR-10-016 currently open for applications?
No. The archive date indicates this is an archived historical FOA rather than an open competition today.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide page associated with PAR-10-016.
Browse more opportunities from the same category: Education Environment Health
Next opportunity: NEI Clinical Study Planning Grant Program (R34)
Previous opportunity: Disability and Rehabilitation Research Projects and Centers Program Field Initiated (FI) Projects CFDA 84.133G 2 (Development).
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 016
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 016) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition for the Global Research Initiative Program, Basic/Biomedical Sciences (R01) Apply for PAR 10 278 Funding Number: PAR 10 278 Agency: National Institutes of Health Category: Education Environment Health Funding Amount: Case Dependent |
| Deepwater Horizon Disaster Research Consortia Health Impacts and Community Resiliency (U19) Apply for RFA ES 11 006 Funding Number: RFA ES 11 006 Agency: National Institutes of Health Category: Education Environment Health Funding Amount: $1,200,000 |
| Superfund Hazardous Substance Research and Training Program (P42) Apply for RFA ES 10 010 Funding Number: RFA ES 10 010 Agency: National Institutes of Health Category: Education Environment Health Funding Amount: Case Dependent |
| Innovative Bioavailability Assays to Assess the Effectiveness of Contaminated Sediment Remediation (R01) Apply for RFA ES 11 005 Funding Number: RFA ES 11 005 Agency: National Institutes of Health Category: Education Environment Health Funding Amount: $200,000 |
| Limited Competition Fogarty International Research Collaboration Basic Biomedical (FIRCA BB) Research Award (R03) Apply for PAR 11 037 Funding Number: PAR 11 037 Agency: National Institutes of Health Category: Education Environment Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Senior Fellows (Parent F33) Apply for PA 11 114 Funding Number: PA 11 114 Agency: National Institutes of Health Category: Education Environment Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 016", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.